Incidence of infection during efalizumab therapy for psoriasis: Analysis of the clinical trial experience

The present review of the available Phase III clinical trial suggests that efalizumab is not associated with an increased risk for infection in patients receiving initial or long-term (27-month) treatment for moderate to severe chronic plaque psoriasis.